calreticulin-directed vaccines how they may impact mpn treatment
Published 2 years ago • 333 plays • Length 1:32Download video MP4
Download video MP3
Similar videos
-
1:12
the potential of targeting mutant calreticulin with antibodies in mpns
-
1:39
germline predisposition to clonal hematopoiesis and its role in leukemia progression
-
1:02
the use of car-t cell products in a real-world setting
-
1:43
the addition of immunotherapy to the front-line treatment of as hodgkin lymphoma
-
1:30
a phase i trial of voruciclib /- venetoclax for the treatment of nhl and aml
-
1:31
frontline treatment for cll: the changing paradigm
-
2:49
the importance of vaccination and vaccine responsiveness in patients with cll
-
1:17
the evolution of frontline treatment for cll: from chemoimmunotherapy to targeted agents
-
6:16
allogeneic stem cell transplant: kat's story
-
28:55
aging and disease
-
5:21
challenges in the treatment and management of et and the need to improve therapeutic approaches
-
1:04
clad-ldac-ven induction therapy in aml: insights from a phase ii trial
-
1:21
the role of transplant in the era of new treatments for lymphoma and cll
-
1:12
working towards health equity in sickle cell disease: addressing discrimination and bias
-
2:18
treating patients with advanced-stage hl in the frontline and relapsed settings in 2024
-
1:19
a pilot trial investigating a digital health intervention in patients with cll
-
3:03
the evolution of treatment patterns and prognostic biomarkers in latin american cll patients
-
4:50
timing of driver mutations and clonal dynamics in mpns: a new paradigm for blood cancer development
-
0:48
b-cell receptor signaling proteins as biomarkers of progression in cll
-
5:52
session highlights: disparities in hematology care & lessons learned from ukraine
-
1:25
the potential of triplet regimens combining btkis with venetoclax and obinutuzumab in cll
-
1:18
involving the patient in treatment decisions for cll